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Abstract
Background. Telangiectasia is the dilation of dermal capillaries mainly due to hypertension and vein insufficiency. Treatments of
choice for this condition are sclerotherapy with foam liquid or intradermal fiber optic laser energy delivery. Aim. The aim of this
study was to assess the efficacy of a new therapeutic approach consisting in the use of polymerized hyaluronic acid mesotherapic
injections following sclerotherapy in the areas of the skin affected by telangiectasia in patients without major vein insufficiency.
Materials and Methods. A total of 20 women, aged between 19 and 64 years, affected by recurrent lower leg telangiectasia,
were included in this study. Patients were preliminarily submitted to echo color Doppler sonography to rule out severe
saphenofemoral valve and lower limb major vein insufficiency. All patients underwent 3 sessions a month of polidocanol 1%
capillary injections for 2 months. This was followed by 0.1 ml cross-linked hyaluronic acid introduction in the polidocanol 1% needle track. A total of 50 mesotherapic injections (0.05 ml each) were performed on the skin surface where an ice pack was previously applied for 4 to 5 minutes. A follow-up visit was performed at 3 months. The results, based on photographic examination,
were rated as follows: poor improvement (0%-50%), good improvement (51%-75%), and very good improvement (76%-100%).
The side effects of the clinical procedure, in terms of pain, itching, paresthesia, ecchymosis, and relapse of telangiectasia over the
treated skin surface, as well as a persisting pigmentation in the injection spots and induced benefits related to leg heaviness and
comfort, were recorded. Results. In total, 6 patients displayed a slight venous insufficiency, 3 patients displayed patent venous
insufficiency, and 11 patients did not show any venous insufficiency. Before treatment, itching was present in 18 out of 20 patients,
paresthesia in 15 out of 20 patients, ecchymosis in 16 out of 20 patients, and leg heaviness in 15 out of 20 patients. At the 3-month
follow-up, an improvement of 0% to 50% was observed in 4 patients who had a relapse in telangiectasia. A 51% to 75% improvement was observed in 3 patients and a 76% to 100% improvement occurred in 13 patients. At the 3-month follow-up, itching
persisted only in 4 patients; paresthesia was absent in 12 patients, while 3 patients still presented this symptom; ecchymosis was
absent in 16 patients; 15 patients reported a feeling of lightweight legs. Among the patients with relapsing telangiectasia, 2 patients
reported pigmentation due to hemosiderin deposit in the skin at the 3-month follow-up. The slight venous insufficiency, observed
at the beginning of the study, improved in 5 out of 6 patients. The patients’ compliance with the procedure was high and 16 out of
20 patients declared their willingness to repeat the whole clinical procedure, if necessary. Conclusions. This pilot clinical study
supports the use of hyaluronic acid mesotherapic injections following sclerotherapy for treatment of lower leg telangiectasia without major venous insufficiency. We propose that the prolonged persistence of cross-linked hyaluronic acid, across the microvascular venous areas, is able to induce a stronger stromal tissue, thus preventing relapse. Further clinical studies, comparing this new
approach with existing clinical procedures, are needed in a larger number of patients.
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Introduction
Telangiectasia is the dilation of dermal capillaries mainly due
to hypertension and vein insufficiency. Skin telangiectasia is
an aesthetic defect characterized by an unpleasant appearance,
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Figure 1. Cross-linking polymer reaction of sodium hyaluronate with divinyl sulfone (DVS; permission to reproduce this picture has been
obtained from Adoderm GmbH, Langenfeld, Germany).

but it is also characterized by discomfort, itching, and a high
rate of bruising.1 Nowadays, sclerotherapy with foam liquid
and external or intradermal fiber optic laser energy delivery
represents the ‘‘gold standard’’ treatment.2,3 We hypothesize
that application of highly cross-linked hyaluronic acid (HA)
mesotherapic injections, directly into the dermis affected by
telangiectasia, may enhance the capillary network and support
the stromal tissue. HA is a natural glycosaminoglycan synthesized by the cell membrane and released into the extracellular
matrix.4 This polysaccharide is present in all the living organisms where it plays a key structural function. It is made up of
disaccharidic units (structure: [D-glucuronic acid (1-b-3) Nacetyl-D-glucosamine (1-b-4)]n) that can polymerize to give
a high-molecular-weight compound.5 In humans, native HA
is internalized in stromal cells mainly through interaction with
CD44 receptor and, subsequently, it is rapidly metabolized and
hydrolyzed by hyaluronidase and glucosidase activity.6 In
order to obtain a more resistant filler that is able to remain longer inside the human body, HA needs to be stabilized by a
cross-linking process that leads to the formation of a
viscous gel.7 Cross-linked HA is less soluble in water and
exerts a long-standing biomechanical effect since it is slowly
degraded.8 For this reason, in order to obtain a more effective
and long-lasting result, we selected a highly cross-linked HA,
that is, Variofill (Adoderm GmbH, Langenfeld, Germany), a
safe and widely used cosmetic filler available in 10-ml syringes
(concentration 33 mg/ml).
Variofill is produced from a 33 mg/ml solution of non-crosslinked HA (106 Da). This solution undergoes extensive crosslinking with divinyl sulfone (DVS; up to 80% cross-linking;
Figure 1). Afterwards the DVS is completely washed out. The
highly concentrated and cross-linked HA obtained, which is
characterized by a significantly higher viscosity compared to

the initial mixture, is subsequently formed into particles and
stabilized to obtain a pure cross-linked HA, that is, Variofill.
This method is described as new monophasic particle technology (MPT).

Aim
We tested the hypothesis that small filler drops injected through
a targeted filler-based mesotherapy, would improve the cosmetic
and functional appearance of the leg, especially in cases of telangiectasias without major venous insufficiency. The present
study was designed to determine, for the first time, the effect
of mesotherapic injections of HA in the areas of the skin affected
by telangiectasia after sclerotherapy in patients without major
venous insufficiency. The rationale of this study is to support the
venous microvascular network with cross-linked HA injections
in the spots, where dilated microvessels arise inducing a stronger
fibroblastic framework in the interstitial tissue, avoiding dilation
of capillaries.

Materials and Methods
The present study was performed at the Poliambulatorio del
Secondo Parere (Modena, Italy). This study was performed
according to the Helsinki Declaration and approved by the
local Internal Review Board. All patients signed the informed
consent before the beginning of the procedure.

Patients
A total of 46 women, affected by lower leg telangiectasia, were
screened. Inclusion criteria for the present study were multiple,
bilateral, and symptomatic lower leg telangiectasia without
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Figure 2. Patient before (A) and after (B) treatment (rated as poor improvement). Telangiectasia and capillary network dilations are still present
after treatment.

major venous insufficiency. Exclusion criteria were HA and
polidocanol allergy, dermatitis due to lymphovenous
insufficiency, pregnancy, cutaneous dyschromia, severe renal
and cardiorespiratory insufficiency, diabetes and body mass
index >25.

Intervention
All patients underwent the following protocol:
polidocanol 1% (Aethoxyscklerol, Chemiske Fabric Kreussler & Co. GmbH, Germany) capillary injections (3
sessions a month for 2 months);
disconnection of the polidocanol 1% syringe leaving the needle in place;
0.1 ml cross-linked HA (Variofill, Adoderm GmbH,
Langenfeld, Germany) precharged syringe introduction
in the polidocanol 1% needle track;
a total of 50 mesotherapic injections (0.05 ml each) on the
treated skin area where an ice pack was previously applied
for 4 to 5 minutes for a total of 3 sessions a month.
In case of patients displaying slight venous insufficiency,
mesotherapy was concentrated around the minor refluxing
venous trunks.

Outcome Evaluation/Follow-up
The following 4 parameters were analyzed: itching, paresthesia, leg heaviness, and recurring presence of ecchymosis.
Patients were preliminarily submitted to echo color Doppler
sonography to rule out severe saphenofemoral valve and lower
limb major venous insufficiency. A follow-up visit was performed at 3 months after the end of treatment to evaluate the
cosmetic and functional effects of the procedure. This was
assessed by means of photographic examination conducted
by 2 dermatologists for the whole duration of the study. The
results, based on photographic examination, were rated as

follows: poor improvement (0%-50%), good improvement
(51%-75%), and very good improvement (76%-100%). The
side effects of the clinical procedure, in terms of pain, itching,
paresthesia, ecchymosis and relapse of telangiectasia over the
treated skin surface, as well as a persisting pigmentation in
the injection spots and induced benefits related to leg heaviness, were recorded. At the end of the clinical course of treatment, patients were asked whether they were willing, if
necessary, to undergo the whole procedure again so as to understand the patient’s compliance with the clinical procedure.

Results
Only 20 women, aged between 19 and 64 years, (45.9 + 2.6
[mean + standard error of mean (SEM)]), complied with inclusion/exclusion criteria and were included in the present
investigation.
After echo color Doppler examination, 6 patients displayed
a slight venous insufficiency and 3 patients displayed patent
venous insufficiency. The other 11 patients did not show any
venous insufficiency. Patients presented a mean of 12 + 0.7
(mean + SEM; range: 6-18) areas of telangiectasia. They were
distributed on the volar part of the tibial bone and on the ventromedial and posterolateral part of the thigh; vessel diameters
were in the range of 0.4 to 5.0 mm. Before treatment, itching
was present in 18 out of 20 patients, paresthesia in 15 out of
20 patients, ecchymosis in 16 out of 20 patients, and leg heaviness in 15 out of 20 patients. Photographic examination, at the
3-month follow-up revealed 0% to 50% improvement in 4
patients (these patients presented a relapse in telangiectasia;
they reported an improvement in the treated sites, but new areas
affected by telangiectasia appeared in the surrounding areas;
Figure 2), 51% to 75% improvement in 3 patients (Figure 3),
and 76% to 100% improvement in 13 patients (Figure 4), as
determined by the 2 dermatologists involved in this investigation. At the 3-month follow-up, itching persisted only in 4
patients; paresthesia was absent in 12 patients, while 3 patients
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Figure 3. Patient before (A) and after (B) treatment (rated as good improvement; amelioration of the microvascular network with reduction of
telangiectasia).

Figure 4. Patient before (A) and after (B) treatment (rated as very good improvement; disappearance of dilated subdermal microvessels).

still presented this symptom; ecchymosis was absent in all the
sixteen patients; 15 patients reported a feeling of lightweight
legs. No foreign body reaction was observed among the
patients involved in this study. Among the 4 patients with
relapsing telangiectasia, 2 patients reported pigmentation due
to hemosiderin deposit in the skin at the 3-month follow-up.
At the beginning of the study, these patients presented slight
venous insufficiency (1 case) and patent venous insufficiency
(3 cases). The slight venous insufficiency, observed at the
beginning of the study, improved in 5 out of 6 patients. During
the clinical procedure, all the patients manifested high compliance to continue with treatment regimen. At the end of the
study, 16 out of 20 patients declared their willingness to repeat
the whole clinical procedure, if necessary.

Conclusions
The present study investigated the effect of a new procedure
based on a combination of HA injections and sclerotherapy for
treatment of telangiectasia. This study was performed in

women, rather than in men, since for them, in our experience,
lower leg telangiectasia represents a much heavier burden to
bear because of the aesthetic component of the disease that
makes them more enthusiastic about the idea of a new
procedure. In our cohort of 20 patients, good to very good
results were reported in 16 patients, as assessed by 2 dermatologists at the 3-month follow-up. Overall, a complete remission
of leg heaviness and ecchymosis was observed in those patients
presenting these symptoms prior to the procedure. Itching and
paresthesia persisted only in 4 out of 18 and 3 out of 15
patients. According to the present preliminary study, the procedure, based on HA mesotherapic injections and sclerotherapy,
was safe and the majority of the patients showed high
compliance in repeating the entire course of treatment. These
findings strongly support the use of this procedure for improving hydrophilia and elasticity of the stroma and counteracting
newly formed areas of telangiectasia and relapses. However,
4 patients showed a relapse in their condition, which may be
due to further hemodynamic changes of the lower leg
microcirculation. Two patients reported a relevant weight gain
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(5 and 6 kg, respectively) and changes in lifestyle with strong
reduction in physical activity that may have negatively influenced the microcirculation.
This study emphasizes the potential role of the dermal and
subcutaneous stromal tissue in supporting the microcirculatory
network in a tense viscoelastic environment suitable to
maintain, in the long run, the cosmetic restoration of the treated
legs. In fact, in our group the 3-month follow-up showed the
good persisting outcome of sclerotherapy when supported, in the
treated area, by adequate mesotherapy with cross-linked HA.
Furthermore, the improvement in slight venous insufficiency,
observed in 5 out of 6 patients, confirms that a stronger and more
elastic support of the interstitial tissue, in the HA-treated areas,
can improve or even restore the physiological venous drainage.
In these patients the results lasted until 3 months. On the basis of
the results from the present pilot clinical study, we can outline
three potential indications of cross-linked HA injection for treatment of lower leg telangiectasia: (1) HA could be used as an
intermittent treatment every 3 to 6 months after sclerotherapy
to reinforce the skin texture, avoiding lumen dilation, and thus
preventing the worsening of symptoms and relapse of telangiectasia; (2) it might be a complementary treatment to support and
maintain the capillary permanent obstruction when injected
across the external capillary wall; (3) it might be indicated for
treatment of early telangiectasia, when the intraluminal injection
is not possible because of the extremely thin lumen. In fact, if the
needle is not allowed to enter into the capillary lumen, polidocanol extravascular injection can generate postinflammatory
sclerosis of the stroma, while HA injection in the interstitial
space helps connective tissue to regenerate normal collagen bundles and reticulin.
In conclusion, this pilot study supports the use of HA
mesotherapic injections following sclerotherapy for treatment
of lower leg telangiectasia. We suggest that the prolonged
persistence of cross-linked HA, across the microvascular
venous areas, is able to induce a stronger stromal tissue, thus
preventing relapse. Further controlled clinical studies, comparing the use of HA in comparison with other techniques are
needed in larger cohorts of patients.
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